

CLAIMS

1. Use of erythropoietin or a substance having erythropoietin-like activity in the preparation of a pharmaceutical for the treatment of chronic inflammations.
2. Use according to claim 1, wherein the inflammation is associated with an immune disease.
3. Use according to claim 2 wherein the immune disease is an auto-immune disease.
4. Use according to claim 3, wherein the auto-immune disease is rheumatoid arthritis.
5. Use of erythropoietin or a substance having erythropoietin-like activity in the preparation of a pharmaceutical for the treatment of symptoms associated with rheumatoid arthritis.
6. Use according to claim 5, wherein the symptoms treated comprise at least one of the group of morning stiffness, painful and swollen joints, loss of grip strength and pain.
7. Use of erythropoietin or a substance having erythropoietin-like activity in the preparation of a pharmaceutical for the amelioration of disease activity of rheumatoid arthritis.
8. Use according to ^{claim 1} ~~anyone of the afore going claims~~, wherein the erythropoietin is human erythropoietin.
9. Use according to ^{claim 1} ~~anyone of the aforegoing claims~~, wherein the erythropoietin or the substance having such activity is of recombinant origin.

add
a1

add
B1

add
H3

add
E5

08817704.088597